CIK 0001439222
- Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-02-27 | NELSEN ROBERT Director | Sale | −53,985 | $48.36 | $2.6M | 229,696 |
| 2017-02-27 | NELSEN ROBERT Director | Sale | −83,750 | $49.13 | $4.1M | 145,946 |
| 2017-02-27 | NELSEN ROBERT Director | Sale | −57,488 | $50.28 | $2.9M | 88,458 |
| 2017-02-23 | NELSEN ROBERT Director | Sale | −42,596 | $47.73 | $2.0M | 292,081 |
| 2017-02-23 | NELSEN ROBERT Director | Sale | −8,400 | $48.75 | $409K | 283,681 |
| 2017-02-22 | NELSEN ROBERT Director | Sale | −46,938 | $49.90 | $2.3M | 335,677 |
| 2017-02-22 | NELSEN ROBERT Director | Sale | −1,000 | $50.35 | $50K | 334,677 |
| 2017-02-21 | Schenkein David P Chief Executive Officer | Grant or award · Stock option (right to buy) | +142,900 | 142,900 | ||
| 2017-02-21 | Hoerter Steven L. Chief Commercial Officer | Grant or award · Stock option (right to buy) | +47,600 | 47,600 | ||
| 2017-02-21 | Hirsch Andrew Chief Financial Officer | Grant or award · Stock option (right to buy) | +47,600 | 47,600 | ||
| 2017-02-21 | Bowden Christopher Chief Medical Officer | Grant or award · Stock option (right to buy) | +47,600 | 47,600 | ||
| 2017-02-21 | Biller Scott Chief Scientific Officer | Grant or award · Stock option (right to buy) | +47,600 | 47,600 | ||
| 2017-02-21 | Alenson Carman Principal Accounting Officer | Grant or award · Restricted stock units | +3,300 | 3,300 | ||
| 2017-02-21 | NELSEN ROBERT Director | Sale | −1,780 | $54.17 | $96K | 417,265 |
| 2017-02-21 | NELSEN ROBERT Director | Sale | −34,650 | $50.56 | $1.8M | 382,615 |
| 2017-02-16 | Schenkein David P Chief Executive Officer | Option exercise | +6,000 | $0.30 | $2K | 6,000 |
| 2017-02-16 | Schenkein David P Chief Executive Officer | Sale | −6,000 | $50.01 | $300K | 0 |
| 2017-02-16 | Schenkein David P Chief Executive Officer | Option exercise · Stock option (right to buy) | −6,000 | 201,656 | ||
| 2017-01-26 | Schenkein David P Chief Executive Officer | Grant or award · Stock option (right to buy) | +68,182 | 136,363 | ||
| 2017-01-26 | Biller Scott Chief Scientific Officer | Grant or award · Common stock (right to buy) | +34,090 | 54,090 |
Page 78 of 80 · 1,590 trades